Thrombosis

Featured Article

A 35-Year-Old Pregnant Woman Presents With Progressive Dyspnea and Palpitations

A 35-Year-Old Pregnant Woman Presents With Progressive Dyspnea and Palpitations

A 35-year-old pregnant woman presents to the emergency department with progressive dyspnea and palpitations that have worsened during the last 3 weeks.

Latest Features

Latest News

Pulmonary Embolism Risk Prediction in Postpartum Women

Pulmonary Embolism Risk Prediction in Postpartum Women

Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.

Atrial Fibrillation Treated With LAA Occlusion Reduces Thromboembolism Risk

Atrial Fibrillation Treated With LAA Occlusion Reduces Thromboembolism Risk

Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Catheter-directed thrombolysis vs systemic thrombolysis strategies show different risk outcomes for patients with intermediate-risk pulmonary embolism.

Pediatric Pulmonary Embolism: 9 Predictors Identified

Pediatric Pulmonary Embolism: 9 Predictors Identified

Several clinical predictors of pediatric pulmonary embolism have been identified.

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.

FDA Approves Rivaroxaban 10 mg for Recurrent VTE

FDA Approves Rivaroxaban 10 mg for Recurrent VTE

The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.

Venous Thromboembolism Risk Linked to Lengthy Television Watching

Venous Thromboembolism Risk Linked to Lengthy Television Watching

Watching television frequently is independently associated with an increased risk for venous thromboembolism.

Vessel Sizing Optimization in BVS Implantation

Vessel Sizing Optimization in BVS Implantation

Researchers analyzed 3-year outcomes in patients implanted with bioresorbable vascular scaffolds for the treatment of coronary lesions.

No Difference in Short-Term Outcomes in Saddle vs Nonsaddle Pulmonary Embolism

No Difference in Short-Term Outcomes in Saddle vs Nonsaddle Pulmonary Embolism

Patients with saddle and nonsaddle pulmonary embolism have similar short-term outcomes, despite more serious symptoms being present in saddle pulmonary embolism.

Sign Up for Free e-Newsletters